ZIVO Bioscience (NASDAQ:ZIVO – Get Free Report) and Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.
Insider and Institutional Ownership
12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk & Volatility
ZIVO Bioscience has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Autolus Therapeutics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the S&P 500.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ZIVO Bioscience | $15,850.00 | 2,508.62 | -$7.78 million | ($3.80) | -3.15 |
| Autolus Therapeutics | $1.70 million | 644.88 | -$208.38 million | ($1.20) | -3.43 |
ZIVO Bioscience has higher earnings, but lower revenue than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than ZIVO Bioscience, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ZIVO Bioscience and Autolus Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ZIVO Bioscience | -11,068.75% | N/A | -1,308.44% |
| Autolus Therapeutics | N/A | -66.76% | -36.90% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for ZIVO Bioscience and Autolus Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ZIVO Bioscience | 0 | 1 | 0 | 0 | 2.00 |
| Autolus Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
Autolus Therapeutics has a consensus price target of $8.70, indicating a potential upside of 111.17%. Given Autolus Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than ZIVO Bioscience.
Summary
Autolus Therapeutics beats ZIVO Bioscience on 10 of the 14 factors compared between the two stocks.
About ZIVO Bioscience
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
